TO EVALUATE THE SAFETY AND EFFICACY OF AMLODIPINE AND CHLORTHALIDONE IN COMBINATION WITH TELMISARTAN IN HYPERTENSIVE PATIENTS ATTENDING TERTIARY CARE CENTRE, TELANGANA

Authors

  • VALISHETTI MANOJ KUMAR Department of Pharmacology, Osmania Medical College, Telangana, India https://orcid.org/0000-0003-3229-2848
  • YASARAPU MADHU Department of Pharmacology, Osmania Medical College, Telangana, India
  • MONICA N. Department of Pharmacology, Osmania Medical College, Telangana, India
  • LINGAMPALLY SUVID Department of Pharmacology, Osmania Medical College, Telangana, India https://orcid.org/0000-0003-2364-1057
  • NAGUR SHARONE GRACE Department of Pharmacology, Osmania Medical College, Telangana, India https://orcid.org/0000-0003-2266-8012

DOI:

https://doi.org/10.22159/ijpps.2022v14i11.46070

Keywords:

Hypertension, Telmisartan, Amlodipine, Chlorthalidone

Abstract

Objective: The main objective of this study is to evaluate and compare the effects of both treatments on systolic and diastolic blood pressure in 4th, and 8th weeks with baseline

Methods: A prospective, comparative, Open-label, and parallel-group clinical study was conducted in out patient's department of general medicine at Osmania general hospital. 120 patients were randomly allocated into 2 groups. Group 1 with 60 patients received Tab: Telmisartan 40 mg+Amlodipine 5 mg once daily, and Group 2 with 60 patients received Tab: Telmisartan 40 mg+ Chlorthalidone 6.25 mg once daily for a period of 8 w. Follow-up was done in the 4th week and 8th week to evaluate the safety and efficacy in hypertensive patients.

Results: The differences in the SBP, DBP, and HR in group A (P value<0.001) and group B (P value<0.001) at the 4th week and 8th week follow-up periods with baseline value (0 w) were statistically significant as P value<0.05.

Conclusion: The combination of telmisartan plus amlodipine is equally effective as the combination of telmisartan plus chlorthalidone in decreasing SBP, DBP, HR, and MAP. No major adverse drug reactions were noted during the study period.

Downloads

Download data is not yet available.

References

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi: 10.1016/S0140-6736(05)17741-1, PMID 15652604.

Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014;8(6):HC08-11. doi: 10.7860/JCDR/2014/9352.4500, PMID 25121000.

Park CG, Ahn TH, Cho EJ, Kim W, Kim HS, Yang JY. Comparison of the efficacy and safety of fixed-dose s-amlodipine/telmisartan and telmisartan in hypertensive patients inadequately controlled with telmisartan: a randomized, double-blind, multicenter study. Clin Ther. 2016;38(10):2185-94. doi: 10.1016/j.clinthera. 2016.09.006, PMID 27720505.

Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32(6):1170-7. doi: 10.1097/ HJH.0000000000000146.

Suresh M, Venkat C, Muruganathan A, Kumar MK. Hypertension management in india: an observational study. Journal of the American College of Cardiology. 2019;73(9). doi: 10.1016/ S0735-1097(19)32330-7.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. Seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2, PMID 14656957.

Prabakaran J, Vijayalakshmi N, Venkata Rao E. Prevalence of hypertension among urban adult population (25-64y) of Nellore. Int J Res Dev Health. 2013;1(2):42-9.

Bir Singh P, Singh S, Gill GK. Role of combination drug therapy for management of hypertension with increasing age. Asian J Pharm Clin Res. 2021 Oct;14(10):53-8. doi: 10.22159/ ajpcr.2021.v14i10.42431.

James PA, Oparil S, Carter BL, Cushman WC, Dennison Himmelfarb C, Handler J. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427, PMID 24352797.

Dhaniyala K, Chandra VB, Rayam S. A cross-sectional study of antihypertensive drug utilization pattern in rural population of southern India. Asian J Pharm Clin Res. 2022 Jan;15(3):39-41. doi: 10.22159/ajpcr.2022.v15i3.43912.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2, PMID 14656957.

Sagarad SV, Kerure SB, Kumar SC, Mr R. The antihypertensive efficacy of chlorthalidone and telmisartan in Indian hypertensive patients who were uncontrolled with hydrochlorothiazide and telmisartan combination-a prospective and an open-label study. J Clin Diagn Res. 2013;7(4):687-90. doi: 10.7860/JCDR/2013/5437.2882. PMID 23730647.

Hisatoshi BK Yamamoto, Masayoshi Sone, Tomoki Homma, Masashi Nakata, Masatoshi Nohara. Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension. Oxidative Medicine and Cellular Longevity 2010;3(5):342-6.

Published

01-11-2022

How to Cite

KUMAR, V. M., Y. MADHU, M. N., L. SUVID, and N. S. GRACE. “TO EVALUATE THE SAFETY AND EFFICACY OF AMLODIPINE AND CHLORTHALIDONE IN COMBINATION WITH TELMISARTAN IN HYPERTENSIVE PATIENTS ATTENDING TERTIARY CARE CENTRE, TELANGANA”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 14, no. 11, Nov. 2022, pp. 37-42, doi:10.22159/ijpps.2022v14i11.46070.

Issue

Section

Original Article(s)